Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4994581 | 1.00 | SLC7A5 (0.46) | SLC7A5USP2HSD17B10PKMALOX15 | |
| SCHEMBL1781673 | 0.87 | SLC7A5 (0.44) | SLC7A5USP2HSD17B10PKMALOX15 | |
| Benzoquinone SCHEMBL4317267 | 0.82 | KDM4E (0.62) | SLC7A5USP2HSD17B10PKMALOX15 | |
| SCHEMBL24269408 | 0.80 | USP2 (0.43) | SLC7A5USP2HSD17B10PKMALOX15 | |
| SCHEMBL4308097 | 0.80 | SLC7A5 (0.41) | SLC7A5USP2HSD17B10PKMALOX15 | |
| SCHEMBL4308098 | 0.80 | SLC7A5 (0.41) | SLC7A5USP2HSD17B10PKMALOX15 | |
| SCHEMBL22372474 | 0.75 | SLC7A5 (0.40) | SLC7A5USP2HSD17B10PKMALOX15 | |
| SCHEMBL1076502 | 0.74 | SLC7A5 (0.44) | SLC7A5USP2HSD17B10PKMALOX15 | |
| SCHEMBL5300667 | 0.70 | SLC7A5 (0.44) | SLC7A5USP2HSD17B10PKMALOX15 | |
| SCHEMBL14441259 | 0.70 | SLC7A5 (0.44) | SLC7A5USP2HSD17B10PKMALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533083-B2 | Transient bio-adhesive device for organ monitoring | POSTECH Research and Business Development Foundation (KR) | 2026-01-27 | — | — | US | claimed |
| US-20240124656-A1 | CONDUCTIVE HYDROGEL COMPRISING MUSSEL ADHESIVE PROTEIN AND PREPARATION METHOD THEREOF | POSTECH Research and Business Development Foundation (KR) | 2024-04-18 | — | — | US | claimed |
| US-20240090840-A1 | TRANSIENT BIO-ADHESIVE DEVICE FOR ORGAN MONITORING | POSTECH Research and Business Development Foundation (KR) | 2024-03-21 | — | — | US | claimed |
| US-11814556-B2 | Coacervate formed from catechol-substituted anionic polymer, adhesive comprising same, and method for producing same | POSCO CO., LTD (KR) | 2023-11-14 | — | — | US | claimed |
| EP-3686259-B1 | COACERVATE FORMED FROM CATECHOL-SUBSTITUTED ANIONIC POLYMER, ADHESIVE COMPRISING SAME, AND METHOD FOR PRODUCING SAME | POSCO CO LTD (KR) | 2023-08-30 | — | — | EP | claimed |
| US-20220288271-A1 | BIOADHESIVE COMPOSITION COMPRISING MUSSEL ADHESIVE PROTEIN AND PREPARATION METHOD THEREOF | POSTECH Research and Business Development Foundation (KR) | 2022-09-15 | — | — | US | claimed |
| EP-4743437-A1 | DIESTER LIPIDS, LIPID NANOPARTICLE CONTAINING DIESTER LIPIDS, AND FORMULATIONS THEREOF | Providence Therapeutics Holdings Inc. (CA) | 2026-05-20 | — | — | EP | disclosed |
| CN-122059945-A | Nitrogen-containing heterocyclic compound and organic electroluminescent device thereof | 长春海谱润斯科技股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12625145-B2 | Endometrial receptivity determination | CELVIA CC AS (EE) | 2026-05-12 | — | — | US | disclosed |
| EP-4731258-A1 | LIPID NANOPARTICLES CONTAINING DISULFIDE LIPIDS AND FORMULATIONS THEREOF | Providence Therapeutics Holdings Inc. (CA) | 2026-04-29 | — | — | EP | disclosed |
| EP-4022047-B1 | IMPROVED POLYPEPTIDES CAPABLE OF CONVERTING SUBSTRATE 3-KETO- DEOXYNIVALENOL INTO 3-EPI- DEOXYNIVALENOL | DSM Austria GmbH (AT) | 2026-04-22 | — | — | EP | disclosed |
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260062700-A1 | ENGINEERED RETRONS AND METHODS OF USE | RENAGADE THERAPEUTICS MAN INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-11396656-B2 | Nucleic acid encoding n-methylputrescine oxidase and uses thereof | 22ND CENTURY LIMITED, LLC (US) | 2022-07-26 | — | — | US | disclosed |
| EP-4022047-A1 | IMPROVED POLYPEPTIDES CAPABLE OF CONVERTING SUBSTRATE 3-KETO- DEOXYNIVALENOL INTO 3-EPI- DEOXYNIVALENOL | Erber Aktiengesellschaft (AT) | 2022-07-06 | — | — | EP | disclosed |
| US-20220196670-A1 | ENDOMETRIAL RECEPTIVITY DETERMINATION | CELVIA CC AS (EE) | 2022-06-23 | — | — | US | disclosed |
| US-20220162695-A1 | USE OF DEXTRAMER IN SINGLE CELL ANALYSIS | IMMUDEX APS (DK) | 2022-05-26 | — | — | US | disclosed |
| EP-3969912-A1 | ENDOMENTRIAL RECEPTIVITY DETERMINATION | Tervisetehnoloogiate Arenduskeskus AS (EE) | 2022-03-23 | — | — | EP | disclosed |
| US-20220064226-A1 | Panel comprising Borrelia MHC multimers | IMMUDEX APS (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20220024915-A1 | INHIBITORS OF VAP-1 | ACUCELA INC. | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533083-B2 | Transient bio-adhesive device for organ monitoring | EPCAM, MYLK, MYLK2 | SLC7A5 702/4885USP2 912/4885HSD17B10 4498/4885 |
| US-20220288271-A1 | BIOADHESIVE COMPOSITION COMPRISING MUSSEL ADHESIVE PROTEIN AND PREPARATION METHOD THEREOF | MSN, EPCAM, ICAM1 | SLC7A5 4431/4885USP2 1273/4885HSD17B10 4662/4885 |
| US-20260062700-A1 | ENGINEERED RETRONS AND METHODS OF USE | NSUN3, RNASEH1, TRMT1L | SLC7A5 1205/4885USP2 1480/4885HSD17B10 2227/4885 |
| US-20220024915-A1 | INHIBITORS OF VAP-1 | VAPB, VAPA, TOE1 | SLC7A5 2785/4885USP2 1816/4885HSD17B10 2582/4885 |
| US-12625145-B2 | Endometrial receptivity determination | METAP2, ERAP2, ELANE | SLC7A5 1123/4885USP2 1897/4885HSD17B10 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.